SI
NBIX icon

Scout Investments’s Neurocrine Biosciences NBIX Stock Holding History

Scout Investments’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$23.5M Buy
203,501
+13,631
+7% +$1.87M 0.62% 61
2024
Q2 		$26.1M Buy
189,870
+83,345
+78% +$11.4M 0.7% 44
2024
Q1 		$15.1M Sell
106,525
-155,093
-59% -$21.2M 0.37% 101
2023
Q4 		$34.5M Sell
261,618
-104,199
-28% -$12M 0.86% 29
2023
Q3 		$40.9M Buy
365,817
+13,870
+4% +$1.46M 0.94% 21
2023
Q2 		$35.3M Buy
351,947
+221,618
+170% +$21.7M 0.72% 36
2023
Q1 		$13.2M Sell
130,329
-28,810
-18% -$3M 0.27% 120
2022
Q4 		$19M Sell
159,139
-73,785
-32% -$8.64M 0.39% 86
2022
Q3 		$24.7M Sell
232,924
-8,697
-4% -$882K 0.51% 72
2022
Q2 		$23.6M Hold
241,621
– – 0.47% 79
2022
Q1 		$22.7M Sell
241,621
-7,534
-3% -$639K 0.36% 91
2021
Q4 		$21.2M Sell
249,155
-5,559
-2% -$511K 0.31% 110
2021
Q3 		$24.4M Sell
254,714
-3,904
-2% -$369K 0.36% 104
2021
Q2 		$25.2M Buy
258,618
+56,228
+28% +$5.39M 0.37% 97
2021
Q1 		$19.7M Sell
202,390
-30,445
-13% -$3.19M 0.3% 127
2020
Q4 		$22.3M Sell
232,835
-1,945
-0.8% -$188K 0.41% 90
2020
Q3 		$22.6M Buy
234,780
+61,059
+35% +$7.06M 0.5% 63
2020
Q2 		$21.2M Buy
+173,721
New +$19.2M 0.51% 66

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Scout Investments's NBIX Position: Q3 2024 in Review

Scout Investments increased its Neurocrine Biosciences (NBIX) stake by 7.2% in Q3 2024, buying an estimated $1.87M and bringing the position to 203,501 shares worth $23.5M. The position accounts for 0.62% of the portfolio, ranked #61.

Scout Investments first reported a position in NBIX in Q2 2020 and has held it in 18 quarters since. The position peaked at $40.9M in Q3 2023. 574 funds tracked by Wall St. Rank hold NBIX as of Q3 2024.

  • Scout Investments held 203,501 shares of Neurocrine Biosciences worth $23.5M as of Q3 2024.
  • Scout Investments bought 13,631 Neurocrine Biosciences shares in Q3 2024, an estimated $1.87M.
  • Neurocrine Biosciences made up 0.62% of Scout Investments's portfolio in Q3 2024, its #61 holding.
  • Scout Investments first reported a position in Neurocrine Biosciences in Q2 2020 and has held it in 18 quarters since.
  • Scout Investments's Neurocrine Biosciences position peaked at $40.9M in Q3 2023.
  • 574 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2024.

Based on Scout Investments's 13F filing for Q3 2024, filed 12 Nov 2024.